Here, we investigate and identify a mechanism by which ALK4 loss enhances TGF-β signaling and promotes cancer progression in pancreatic and triple-negative breast cancers, offering new insights into potential therapeutic approaches targeting TGF-β signaling pathways in these cancer types. This evidence concerns the gene ACVR1B and triple-negative breast carcinoma.